John Whelan
Pediatric Rheumatology Santa Monica, CA Medical Doctor
NPI 1083681258 CMS profile 707802
1250 16Th St # C2304, Santa Monica, CA 90404
General payments
$122
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, John Whelan of Santa Monica, CA is reported in the CMS Open Payments database as having received $122 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 24th percentile of Pediatric Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $122 | 1 |
Beside peers
- John Whelan
- Pediatric Rheumatology median
- Middle half of Pediatric Rheumatology
- National median
In program year 2025, general payments to John Whelan were reported at $0. Among 204 Pediatric Rheumatology profiles paid that year, the median was $146 and the middle half received between $95 and $522.
Show as a table
| Year | John Whelan | Pediatric Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $141 | $61–$1,029 | $163 |
| 2020 | $0 | $113 | $33–$419 | $114 |
| 2021 | $0 | $189 | $61–$1,640 | $132 |
| 2022 | $0 | $120 | $28–$404 | $149 |
| 2023 | $122 | $97 | $41–$222 | $160 |
| 2024 | $0 | $139 | $48–$606 | $164 |
| 2025 | $0 | $146 | $95–$522 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
23
Drug cost
$202,487
Branded share of claims
100%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | Brand | 23 | $202,487 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 5 billing codesPaid by Medicare
$3,603
Medicare patients
20
Services billed
27
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Cancer | 55% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Rheumatology in California
William Soulsby
Pediatric Rheumatology · San Francisco, CA
Vivian Saper
Pediatric Rheumatology · Palo Alto, CA
Jennifer Frankovich
Pediatric Rheumatology · Palo Alto, CA
Andrew Shulman
Pediatric Rheumatology · Orange, CA
Peter Chiraseveenuprapund
Pediatric Rheumatology · San Diego, CA
Andreas Reiff
Pediatric Rheumatology · Los Angeles, CA
Related records
Pediatric Rheumatology in California
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.